Maintz L, Novak N
Fisk HL, Childs CE, Miles EA, Ayres R, Noakes PS, Paras-Chavez C, et al
In recent months, semaglutide-containing medications have grown in popularity, in part due to reported use by celebrities
That means they are not subject to GMP or the quality control requirements that come with it
HbA1c reductions up to 1.6 percentage points Weight trajectory: Weight loss had not plateaued by 52 weeks, indicating potential for further reduction with continued treatment Cardiometabolic: Improvements in waist circumference, blood pressure, hs-CRP, and lipid parameters Evidence level: Moderate -- well-designed phase 2 with NEJM publication, but single trial, no head-to-head comparisons